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Bone Sarcoma Cumulative Tumor Rates in Patients 
Injected with 2 2 4 R a * 
C. W. Mays, H. Spi ess, D. Chmelevsky, A. Kell er er 
Introduction 
This paper serves as an overview for the Sym-
posium's other 5 papers on the biological effects of 
2 2 4 R a in German patients [1, 12, 17, 19, 22]. It will 
deal specifically with the follow-up, started by 
Spiess in 1952, of 899 children and adults who 
received weekly or twice-weekly intravenous in-
jections of 2 2 4 R a , mainly for the treatment of tuber-
culosis and ankylosing spondylitis. 2 2 4 R a is an 
a-emitting isotope of radium with a half-life of 
3.62 days. The dose from 2 2 4 R a and its decay 
products has been calculated [6, 8, 14] but may 
require future revision when reliable values have 
been established for the in-vivo escape of the decay 
products from bone [6, 11]. The patients are con-
tacted by mail questionnaire, and we verify their 
diseases with help from their physicians, hospitals, 
and health offices [8, 13]. 
* Supported by U.S. Department of Energy Contract DE-
AC02-76EV-00119 and E U R A T O M Contract BI -D-
461-D(B). 
Table 1. Summary of the Spiess 
" 4 R a Patients (June 1984) 
Status of the Spiess Patients 
Table 1 summarizes the follow-up to June 1984. 
The follow-up times, from first injection to death or 
last known health status, ranged from 0 to 38 years 
and averaged 22 years. Half of these patients are 
known to have died. The injected dosage in juCi/kg 
averaged twice as high in the juveniles as in the 
adults, but because of the enhanced uptake of 2 2 4 R a 
in growing bone, the calculated skeletal dose in 
rads for juveniles averaged 5 times that for the 
adults. 
Table 2 lists diseases of increased incidence. The 
numbers of naturally-expected malignancies were 
calculated from the person-years post injection and 
the cancer incidence rates in the German Democra-
tic Republic [20]. Bone sarcomas were reported in 
53 patients compared to only 0.2 case naturally 
expected. Thus all, or virtually all, of these bone 
sarcomas can be regarded as radiation induced. The 
last bone sarcoma occurred in 1974, 25 years after 
2 2 4 R a injection, and no additional bone sarcomas 
Age at First Injection 
1-20 yr Adult Total 
218 681 899 
81 369 450 
28 15 18 
1062 206 416 
35 18 53 
28 0 28 
28 0 28 
27 17 44 
9 59 68 
0 5 5 
8 56 64 
2 23 25 
12 32 44 
Traced patients 
Deaths 
Av. inj . 2 2 4 Ra (uCi/kg) 




Severe growth retardation 
Tooth breakage 
Soft-Tissue Diseases 
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TUBERCULOSISr 
(ADULTS) • 
TIME AFTER 1st INJECTION (YEARS) 
Fig. 1: Bone sarcoma cumulative 
tumor risks in the major classifica-
tions of the 2 2 4 Ra patients. The 
cumulative risk per gray (or 100 rad) 
progressively increased with time and 
was similar among the various clas-
sifications of patients. Thus, the sus-
ceptibility to bone sarcoma-induction 
was relatively independent of age at 
irradiation, sex. or whether the origi-
nal disease during treatment was 
tuberculosis or ankylosing spondy-
litis. 
confirmed - based on our dosimetric assumptions, 
the age at irradiation, sex, and original disease state 
had no significant influence on the susceptibility to 
2 2 4Ra-induced bone sarcoma. Reprints of the previ-
ous, more detailed analysis are available from C. 
W. Mays [ 8 ] . 
Summary 
At 3 year intervals the health status is updated for 
899 German patients who received repeated injec-
tion of 2 2 4 R a , mostly for the treatment of tuber-
culosis and ankylosing spondylitis. The follow-up 
times, from first injection to death or last known 
health status, ranged from 0 to 38 years and aver-
aged 22 years as of June 1984. The 0-3 excess 
cases of leukemia attributable to 2 2 4 R a is small 
compared to the 53 patients developing bone sar-
comas. Kidney cancers occurred in 4 patients vs. 1 
case naturally expected, whereas nonmalignant 
kidney diseases (usually fatal) were reported for 64 
patients vs. 3 cases naturally expected. Additional 
disease conditions of elevated frequency were: 
liver diseases, cataracts, tooth breakage, benign 
exostoses, and growth retardation. Based on our 
dosimetric assumptions and using the sum-limit 
method to correct for the effects of deaths and 
incomplete follow-up, no statistically-significant 
differences were found in the bone sarcoma risk per 
rad between (a) juveniles vs. adults, (b) males vs. 
females, and (c) TB patients vs. ankylosing spon-
dylitis patients. 
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